

- Discussions with leaders:** Arie Beldegrun, MD, looks at his career and current endeavors as a physician and international medical entrepreneur. . . . . *Page 1821*
- Time-varying models for PET:** Morris and colleagues review the history and development of modeling of brain PET data acquired during “nonsteady” states, i.e., when brain conditions change during imaging. . . . . *Page 1824*
- Evolving practice in melanoma:** Dougherty and colleagues provide an educational overview of guidelines for baseline imaging in newly diagnosed melanoma, FDA-approved checkpoint inhibitors for advanced melanoma treatment, and optimal use of PET/CT in surveillance of treated disease. . . . . *Page 1838*
- Dosimetry in clinical practice:** Bardies and colleagues make a case for the role of patient dosimetry in molecular radiotherapy to optimize and personalize treatments, meet regulatory requirements on radiation protection, and develop supporting data to improve management. . . . . *Page 1846*
- Outpatient <sup>177</sup>Lu-PSMA treatment:** Zagni and colleagues offer commentary on the feasibility of <sup>177</sup>Lu-PSMA administration as an outpatient procedure for prostate cancer, analyzing safety aspects, advantages, and disadvantages. . . . . *Page 1848*
- Italy and outpatient RPT:** Holzwarth supplements *JNM* commentary by Zagni and colleagues with information on Italian legislation allowing outpatient radiopharmaceutical treatment with <sup>177</sup>Lu-PSMA at the discretion of the physician and local medical physics and radiation protection experts. . . . . *Page 1850*
- Challenges with PSMA RPT:** Jadvar and colleagues review clinical challenges evident since FDA and European approval of PSMA-targeted radiopharmaceutical therapy and suggest criteria that might be fine-tuned to increase the likelihood of favorable response in specific patients. . . . . *Page 1851*
- PET/MRI in breast cancer:** Jannusch and colleagues investigate whether <sup>18</sup>F-FDG PET/MRI in addition to conventional staging leads to changes in therapeutic management of newly diagnosed breast cancer and assess relative diagnostic accuracy in disease staging. . . . . *Page 1855*
- <sup>18</sup>F-FTT kinetics in breast cancer:** Young and colleagues characterize the pharmacokinetics of the PARP-inhibitor <sup>18</sup>F-fluorothantrate in breast cancer, assess optimal image timing for clinical trials, and correlate tracer uptake with matched surgical specimens. . . . . *Page 1862*
- Systemic immunity and [<sup>18</sup>F]F-AraG PET:** Levi and colleagues research the utility of [<sup>18</sup>F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status before starting immunotherapy in non-small cell lung cancer. . . . . *Page 1869*
- Metabolic risk scores in DLBCL:** Vergote and colleagues explore the prognostic value of 4 novel metabolic risk scores in a real-life cohort of diffuse large B-cell lymphoma patients and compare results with the revised International Prognostic Index. . . . . *Page 1876*
- [<sup>68</sup>Ga]Ga-NYM046 PET/CT:** Lou and colleagues investigate the diagnostic efficacy of [<sup>68</sup>Ga]Ga-NYM046 PET/CT in animal models and in patients with clear cell renal cell carcinoma and compare its performance with that of <sup>18</sup>F-FDG PET/CT. . . . . *Page 1884*
- CD70-targeted immuno-PET/CT for ccRCC:** Zhou and colleagues describe the potential of cluster of differentiation 70-targeted immuno-PET/CT imaging as a precise and superior method for evaluating tumor burden and suspected metastases in patients with clear cell renal carcinoma. . . . . *Page 1891*
- [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT:** Michalski and colleagues report on the prognostic value of PET-based biomarkers on [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in patients with aggressive neuroendocrine neoplasms and correlate resulting uptake differences and progression-free survival. . . . . *Page 1899*
- Trop2 immuno-PET/CT in lung cancers:** Huang and colleagues detail development and translation of novel trophoblast cell surface antigen 2 single-domain antibody tracers for differentiation of lung inflammation from cancer. . . . . *Page 1904*
- Intraarterial PRRT in meningioma:** Amerein and colleagues analyze the safety and efficacy of intraarterial peptide receptor radionuclide therapy in patients with advanced, progressive meningiomas. . . . . *Page 1911*
- <sup>213</sup>Bi-FAPI-46 therapy:** Helisch and colleagues provide initial clinical experience with feasibility, tolerability, and response of fractionated <sup>213</sup>Bi-fibroblast activation protein inhibitor-46 treatment in patients with progressive metastatic solid tumors. . . . . *Page 1917*
- PET and mpMRI PCa detection:** Sonni and colleagues describe clinically significant prostate cancers evaluated with PSMA PET/CT and multiparametric MRI, focusing on tumors detected solely by PET/CT and overlooked by mpMRI. . . . . *Page 1923*
- [<sup>177</sup>Lu]Lu-PSMA-617 outcomes:** Muniz and colleagues use real-world clinical data to examine prostate-specific antigen response and overall survival after [<sup>177</sup>Lu]Lu-PSMA-617 therapy in patients with liver metastases from castration-resistant prostate cancer. . . . . *Page 1932*
- Response assessment on early [<sup>177</sup>Lu]Lu-PSMA SPECT:** Swiha and colleagues investigate 4-h imaging as an alternative to 24-h [<sup>177</sup>Lu]Lu-PSMA SPECT/CT for evaluation of treatment response in men with metastatic castration-resistant prostate cancer. . . . . *Page 1939*
- <sup>177</sup>Lu-PSMA-617 SPECT/CT in mCRPC:** Demirci and colleagues analyze the roles of total tumor volumes and new lesions determined by LuPSMA SPECT/CT in early treatment cycles to predict subsequent outcomes in metastatic castration-resistant prostate cancer. . . . . *Page 1945*
- FAP and PSMA in CRPC:** Huang and colleagues evaluate fibroblast activation protein expression in a range of castration-resistant prostate cancer tumors and compare these results with prostate-specific membrane antigen expression. . . . . *Page 1952*
- Exendin PET and insulinoma localization:** Boss and colleagues compare the diagnostic accuracy of <sup>68</sup>Ga-NODAGA-exendin-4 PET/CT with that of routine imaging procedures for localization of insulinomas in patients with endogenous hyperinsulinemic hypoglycemia. . . . . *Page 1959*
- MIRDcell V4:** Katugampola and colleagues present artificial intelligence tools in a new version of their software platform that optimizes a cocktail of radiopharmaceuticals by minimizing the total disintegrations needed to achieve a specific surviving fraction of tumor cells. . . . . *Page 1965*
- uMI Panorama GS performance:** Zhang and colleagues detail performance assessment of this new long-axial-field-of-view PET system on the basis of National Electrical Manufacturers Association NU 2-2018 and European Association of Nuclear Medicine Research Limited standards. . . . . *Page 1974*
- CT enhancement of nasal leech:** Meng and He share a case study of a patient who, after thrombectomy, was discovered to have had a contrast-enhancing leech in the left nostril. . . . . *Page 1983*